Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.58 |
| ▸ | MPO | P05164 | 11/20 | 0.55 |
| ▸ | HTR2A | P28223 | 3/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2112913 | 0.83 | GPR84 (0.58) | GPR84HTR2A | |
| SCHEMBL25045531 | 0.78 | SLC6A4 (0.47) | GPR84HTR2AHTR1ASLC6A4 | |
| SCHEMBL20584073 | 0.78 | GPR84 (0.62) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL9268634 | 0.76 | NR4A2 (0.68) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL16697905 | 0.76 | GPR84 (0.57) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL208748 | 0.75 | GPR84 (0.58) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL14631802 | 0.75 | GPR84 (0.58) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL1372357 | 0.75 | GPR84 (0.58) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL15623086 | 0.75 | GPR84 (0.58) | GPR84MPOHTR2ATRPM8HTR1A | |
| SCHEMBL3624363 | 0.75 | MPO (0.59) | GPR84MPOHTR2ATRPM8HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570632-B2 | Indole derivatives and uses thereof for treating a cancer | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2026-03-10 | — | — | US | disclosed |
| EP-4175718-B1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIV CLAUDE BERNARD LYON (FR) | 2024-10-02 | — | — | EP | disclosed |
| CN-115843271-B | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2024-08-13 | — | — | CN | disclosed |
| EP-3583644-B1 | ELECTRODE MATERIALS AND PROCESSES FOR THEIR PREPARATION | HYDRO QUEBEC (CA) | 2024-08-07 | — | — | EP | disclosed |
| EP-4090660-B1 | QUINOXALINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2024-01-31 | — | — | EP | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| EP-3805214-B1 | JAK3 SELECTIVE INHIBITOR | UNIV PEKING SHENZHEN GRADUATE SCHOOL (CN) | 2023-07-05 | — | — | EP | disclosed |
| EP-4175718-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD - LYON 1 (FR) | 2023-05-10 | — | — | EP | disclosed |
| CN-115843271-A | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2023-03-24 | — | — | CN | disclosed |
| EP-3805214-A1 | JAK3 SELECTIVE INHIBITOR | Peking University Shenzhen Graduate School (CN) | 2021-04-14 | — | — | EP | disclosed |
| US-20200052302-A1 | ELECTRODE MATERIALS AND PROCESSES FOR THEIR PREPARATION | HYDRO-QUéBEC (CA) | 2020-02-13 | — | — | US | disclosed |
| US-20200052302-A1 | ELECTRODE MATERIALS AND PROCESSES FOR THEIR PREPARATION | HYDRO-QUéBEC (CA) | 2020-02-13 | — | — | US | disclosed |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | MOLECULAR SKIN THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| WO-2018148833-A1 | ELECTRODE MATERIALS AND PROCESSES FOR THEIR PREPARATION | HYDRO-QUéBEC (CA) | 2018-08-23 | — | — | WO | disclosed |
| EP-2961742-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-1827427-B1 | ARYLOXYETHYLAMINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARM BV (NL) | 2008-07-23 | — | — | EP | disclosed |
| US-20070142397-A2 | PHENYPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
| US-20070142397-A2 | PHENYPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-06-21 | — | — | US | disclosed |
| WO-2006061379-A1 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200052302-A1 | ELECTRODE MATERIALS AND PROCESSES FOR THEIR PREPARATION | ALPL, EPCAM, MB | GPR84 4720/4885MPO 85/4885HTR2A 4453/4885 |
| US-12570632-B2 | Indole derivatives and uses thereof for treating a cancer | CKS2, CSNK2A3, CSNK1A1L | GPR84 1655/4885MPO 4458/4885HTR2A 179/4885 |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | CSNK2A1, IDO1, CSNK2A3 | GPR84 1862/4885MPO 4538/4885HTR2A 293/4885 |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | AIFM2, GPX4, GPX1 | GPR84 2869/4885MPO 326/4885HTR2A 3059/4885 |
| US-20070142397-A2 | PHENYPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | HTR2C, HTR2A, HTR5A | GPR84 203/4885MPO 4022/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.